Characteristics and Treatment of Bone Metastases in 322 Cases Non-small Cell Lung Cancer:A Retrospective Study
10.3779/j.issn.1009-3419.2014.09.03
- VernacularTitle:322例非小细胞肺癌骨转移临床特点及治疗的回顾性分析
- Author:
GUO QINGZHI
1
;
WU MEINA
;
AN TONGTONG
;
ZHAO JUN
;
DUAN JIANCHUN
;
WANG ZHIJIE
;
WANG SHUHANG
;
WANG JIE
Author Information
1. 100142 北京，北京大学肿瘤医院暨北京市肿瘤防治研究所胸部肿瘤内科，恶性肿瘤发病机制及转化研究教育部重点实验室
- Keywords:
Lung neoplasms;
Bone metastases;
ECT;
CT;
MRI;
X-ray
- From:
Chinese Journal of Lung Cancer
2014;(9):656-662
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Bone metastases are the most common metastases of the non-small cell lung cancer (NSCLC). It can lead to bone ache and pathology fracture, deteriorate the quality of life. Methods We retrospec-tively investigated the characteristics, diagnosis and prognosis factors of bone metastases in NSCLC. All of the 600 patients are from department of thoracic oncology in recently 5 years. Emission computed tomography (ECT) was used to screen the bone metastases and the diagnosis of bone metastases was conifrmed by computed tomography (CT)/magnetic resonance imaging (MRI)/X-ray or pathology. Results Among the total 322 bone metastases patients, subtype of adenocarcinoma had the most opportunity to occur bone metastases, and we found that vertebrae, pelvis and femora et al were the most frequently involved metastases sites. Patients who had more than 3 high 18F-FDG uptake sites of ECT, could be conifrmed bone metasta-ses by CT/MRI/X-ray than those with 1-2 high 18F-FDG uptake sites [80.6%(203/252) vs 50.79%(32/63), P<0.001]. hTe patients with bone metastases who had non-SRE had longer survival than that of SRE [1-yr survival 44.75%(non-SRE) vs 36.17%(SRE);median survival 14.74 mo (non-SRE) vs 12.25 mo (SRE)]. Multivariables analysis showed the pathology were non-adnocarcinoma, bone metastases less than 3 sites and bone metastases without other organs metastases would have good prognosis. Conclusion hTere were relations between the numbers of abnormal dense sites of ECT and the diagnosis of skeletal metastases, non-adnocarcinoma bone metastases less than 3 sites and bone metastases without other organs metastases were the independent prognosis factors.
